Lipistad

Atorvastatin, the active ingredient in Lipistad, is a HMG‑CoA reductase inhibitor presented as an oral tablet for systemic use. It lowers elevated cholesterol and triglyceride levels and is prescribed for adults with primary or secondary lipid disorders to reduce cardiovascular risk.

GNH USA supplies Lipistad as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide. The company adheres to stringent quality standards and provides reliable logistics for global distribution. Customers benefit from consistent product availability and regulatory support across multiple markets.

Atorvastatin is indicated for disorders of lipid metabolism and for cardiovascular risk reduction.

- Hypercholesterolemia: reduces low‑density lipoprotein (LDL) cholesterol to target levels. - Mixed dyslipidemia: lowers LDL cholesterol while modestly raising high‑density lipoprotein (HDL) and reducing triglycerides. - Primary prevention of cardiovascular disease: decreases the incidence of myocardial infarction, stroke and related events in at‑risk patients. - Secondary prevention of cardiovascular disease: limits recurrent events in patients with established coronary artery disease or stroke.

Atorvastatin may cause a range of adverse reactions, which are classified by frequency and severity.

Common Side Effects: - Headache: mild to moderate pain in the head region. - Myalgia: muscle aches without weakness. - Gastrointestinal discomfort: nausea, abdominal pain or constipation. - Elevated liver enzymes: mild increase in ALT or AST.

Serious or Rare Side Effects: - Rhabdomyolysis: severe muscle breakdown that can lead to kidney injury. - Acute liver injury: marked elevation of hepatic enzymes or hepatitis. - Allergic reactions: rash, pruritus, angioedema or anaphylaxis.

When prescribing Lipistad, clinicians should observe several safety considerations to minimize risk. - Pregnancy: contraindicated (Category X); avoid use in pregnant women. - Liver disease: assess hepatic function before initiation and monitor regularly. - Renal impairment: dose adjustment may be required in severe renal insufficiency. - Drug interactions: review concomitant medications that affect CYP3A4 metabolism. - Monitor lipid levels: periodic testing to evaluate therapeutic response. - Store at ambient temperature: keep below 25 °C in the original container, protected from moisture and light.

Atorvastatin interacts with several medicines; some combinations require avoidance while others need careful monitoring.

Major Interactions (Avoid): - Strong CYP3A4 inhibitors (e.g., itraconazole, clarithromycin, ritonavir): can markedly increase atorvastatin exposure. - Gemfibrozil: synergistic risk of myopathy and rhabdomyolysis. - Colchicine: elevated risk of severe toxicity when combined.

Moderate Interactions (Monitor Closely): - Antacids containing aluminum or magnesium: may reduce atorvastatin absorption. - Warfarin: potential enhancement of anticoagulant effect, requiring INR monitoring. - Niacin: may increase risk of hepatotoxicity.